#doravirine

Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

The new drug application is for doravirine as both an individual tablet and part of a combination tablet.

The new single-tablet NNRTI regimen was less likely than Atripla to cause neurological symptoms.

Used as a part of a multidrug HIV regimen, the investigational doravirine is also better for cholesterol levels than Norvir/Prezista.